{"id":"bazedoxifene-conjugated-estrogen","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal bleeding/spotting"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bazedoxifene is a SERM that selectively activates estrogen receptors in bone and the cardiovascular system while antagonizing them in breast tissue, reducing breast cancer risk. When combined with conjugated estrogens, it provides systemic estrogen replacement therapy for menopausal symptoms while the bazedoxifene component offers tissue-selective protection against estrogen-related adverse effects in the breast.","oneSentence":"Bazedoxifene acts as a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:30:51.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe vasomotor symptoms associated with menopause"},{"name":"Prevention of postmenopausal osteoporosis"}]},"trialDetails":[{"nctId":"NCT04821375","phase":"EARLY_PHASE1","title":"Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers","status":"COMPLETED","sponsor":"Carol Fabian, MD","startDate":"2021-12-02","conditions":"Increased Risk for Development of Breast Cancer","enrollment":16},{"nctId":"NCT04821141","phase":"PHASE2","title":"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-12-14","conditions":"Risk Reduction, Breast Cancer","enrollment":120},{"nctId":"NCT02274571","phase":"EARLY_PHASE1","title":"Raising Insulin Sensitivity in Post Menopause","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2015-09","conditions":"Menopause","enrollment":8},{"nctId":"NCT02694809","phase":"PHASE2","title":"The PROMISE Study: Duavee in Women With DCIS","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-01","conditions":"Ductal Breast Carcinoma In Situ, Postmenopausal","enrollment":142},{"nctId":"NCT04103476","phase":"PHASE2","title":"Advancing Postmenopausal Preventive Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2021-04-13","conditions":"Atherosclerosis, Cognitive Decline","enrollment":385},{"nctId":"NCT04478305","phase":"PHASE1","title":"Affect of Duavive on Mood & Anxiety Symptoms","status":"RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-07-03","conditions":"Menopause, Depression, Anxiety, Sleep","enrollment":30},{"nctId":"NCT05059626","phase":"PHASE4","title":"Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee","status":"RECRUITING","sponsor":"Penn State University","startDate":"2023-12-01","conditions":"Endometriosis","enrollment":28},{"nctId":"NCT05073237","phase":"PHASE2","title":"Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2024-04-08","conditions":"Menopause, Prediabetes, Obesity","enrollment":""},{"nctId":"NCT02237079","phase":"PHASE4","title":"Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)","status":"COMPLETED","sponsor":"Tulane University Health Sciences Center","startDate":"2014-12","conditions":"Obesity, Glucose Homeostasis, Postmenopausal Symptoms","enrollment":17},{"nctId":"NCT03740009","phase":"PHASE4","title":"Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause\"","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-01-02","conditions":"Perimenopausal Disorder, Depression","enrollment":20},{"nctId":"NCT04036929","phase":"NA","title":"Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis?","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-09","conditions":"Hand Osteoarthritis","enrollment":28},{"nctId":"NCT02729701","phase":"PHASE2","title":"Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2016-05","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT04379024","phase":"EARLY_PHASE1","title":"Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms","status":"TERMINATED","sponsor":"Carol Fabian, MD","startDate":"2020-06-01","conditions":"Focus of Study is Healthy Women at Risk for Breast Cancer","enrollment":11},{"nctId":"NCT02710214","phase":"PHASE2","title":"A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Menopause, Multiple Sclerosis","enrollment":24},{"nctId":"NCT00367536","phase":"PHASE1","title":"Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-08","conditions":"Postmenopause","enrollment":24},{"nctId":"NCT02100553","phase":"PHASE1","title":"Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT00774267","phase":"","title":"Study Evaluating Changes In Mammographic Breast Density","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Osteoporosis","enrollment":507},{"nctId":"NCT00808132","phase":"PHASE3","title":"Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Menopause, Osteoporosis","enrollment":1886},{"nctId":"NCT00242710","phase":"PHASE3","title":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Endometrial Hyperplasia, Osteoporosis","enrollment":1083},{"nctId":"NCT01634789","phase":"PHASE1","title":"A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women","status":"TERMINATED","sponsor":"Pfizer","startDate":"2012-08","conditions":"Healthy","enrollment":2},{"nctId":"NCT00706225","phase":"PHASE1","title":"Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-06","conditions":"Postmenopause","enrollment":30},{"nctId":"NCT00847821","phase":"","title":"Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-05","conditions":"Postmenopause","enrollment":185},{"nctId":"NCT00745173","phase":"PHASE1","title":"Study Evaluating Premarin and Bazedoxifene Potential Interaction","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Postmenopause","enrollment":30},{"nctId":"NCT00675688","phase":"PHASE3","title":"Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-04","conditions":"Endometrial Hyperplasia, Osteoporosis","enrollment":3544},{"nctId":"NCT00550433","phase":"PHASE1","title":"Study Evaluating Bazedoxifene/CE in Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-09","conditions":"Postmenopause","enrollment":""},{"nctId":"NCT00238732","phase":"PHASE3","title":"Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Vaginal Atrophy","enrollment":650},{"nctId":"NCT00464789","phase":"PHASE1","title":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-03","conditions":"Menopause","enrollment":""},{"nctId":"NCT00234819","phase":"PHASE3","title":"Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Vasomotor Symptoms Associated With Menopause","enrollment":325},{"nctId":"NCT00465075","phase":"PHASE1","title":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT00479778","phase":"PHASE1","title":"Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Postmenopause","enrollment":72},{"nctId":"NCT00550303","phase":"PHASE1","title":"Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-10","conditions":"Healthy","enrollment":28},{"nctId":"NCT00396799","phase":"PHASE1","title":"Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-11","conditions":"Menopause","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duavee"],"phase":"marketed","status":"active","brandName":"Bazedoxifene/Conjugated Estrogen","genericName":"Bazedoxifene/Conjugated Estrogen","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bazedoxifene acts as a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief. Used for Moderate to severe vasomotor symptoms associated with menopause, Prevention of postmenopausal osteoporosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}